AFFIDX
LIVE

Serial Number

79304130

Owner

Avacta Limited

Attorney

Christina M. Licursi

Filing Date

Sep 22, 2020

Add to watchlist:

No watchlists yet
View on USPTO

AFFIDX Trademark

Serial Number: 79304130 • Registration: 6829613

AFFIDX is a trademark filed by Avacta Limited on September 22, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Avacta Limited (7 trademarks)

Wetherby LS237FA , GB

Entity Type: 99

Trademark Details

Filing Date

September 22, 2020

Registration Date

August 30, 2022

Published for Opposition

June 14, 2022

Goods & Services

Downloadable software in the nature of mobile application software for medical diagnostics; Downloadable software in the nature of mobile application software for the collection, analysis and reporting of diagnostic tests; downloadable mobile application software for the collection, analysis and reporting of diagnostic tests for Covid-19 and influenza

Diagnostic testing materials, namely diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing, medical diagnostic reagents and assays for testing of body fluids, diagnostic agents, preparations and substances for medical purposes; diagnostic materials being diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing, medical diagnostic reagents and assays for testing of body fluids, diagnostic agents, preparations and substances for medical purposes, preparations for medical testing purposes and test strips for medical testing purposes namely for testing for the detection and diagnosis of covid-19 and influenza; diagnostic materials being diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing, medical diagnostic reagents and assays for testing of body fluids, diagnostic agents, preparations and substances for medical purposes, preparations for medical testing purposes and test strips for lateral flow medical testing purposes namely for the detection and diagnosis of covid-19 and influenza; diagnostic reagents for medical purposes; diagnostic testing materials being diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing, medical diagnostic reagents and assays for testing of body fluids, diagnostic agents, preparations and substances for medical purposes for the detection and diagnosis of covid-19 and influenza; diagnostic preparations for medical testing purposes; materials namely diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing, medical diagnostic reagents and assays for testing of body fluids, diagnostic agents, preparations and substances for medical purposes, and medical diagnostic strips for lateral flow medical testing purposes namely for the detection and diagnosis of covid-19 and influenza, and diagnostic reagents for medical testing purposes, all for the detection and diagnosis of covid-19 and influenza

Medical diagnostic testing being medical testing for diagnostic or treatment purposes, and analysis services namely medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical testing being medical testing for diagnostic or treatment purposes, and analysis services namely medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical diagnostic testing being medical testing for diagnostic or treatment purposes, and analysis services namely medical analysis services for diagnostic and treatment purposes provided by medical laboratories for covid-19 and influenza; medical testing being medical testing for diagnostic or treatment purposes and analysis services namely medical analysis services for diagnostic and treatment purposes provided by medical laboratories for covid-19 and influenza; advisory and information services relating to all the aforesaid

Medical testing apparatus, instruments and equipment for diagnostic use namely apparatus for medical diagnostic testing for the detection and diagnosis of covid-19 and influenza; medical testing apparatus, instruments and equipment for the detection and diagnosis of Covid-19 and influenza, namely medical diagnostic apparatus for testing for viruses, medical diagnostic instruments for the analysis of body fluids, apparatus for virus testing purposes

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Jul 18, 2025 NREP
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 1, 2025 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Jul 1, 2025 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 1, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 1, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jul 1, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jul 1, 2025 COAR
FINAL DECISION TRANSACTION PROCESSED BY IB
Dec 28, 2022 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Dec 7, 2022 FICS
FINAL DISPOSITION PROCESSED
Dec 7, 2022 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Nov 30, 2022 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Aug 30, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
Aug 30, 2022 R.PR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Aug 1, 2022 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jul 13, 2022 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jul 13, 2022 OPNR
NOTIFICATION PROCESSED BY IB
Jul 5, 2022 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 14, 2022 NPUB
PUBLISHED FOR OPPOSITION
Jun 14, 2022 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jun 8, 2022 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jun 8, 2022 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 25, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 9, 2022 CNSA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 9, 2022 GNRN
NON-FINAL ACTION E-MAILED
May 9, 2022 GNRT
NON-FINAL ACTION WRITTEN
May 9, 2022 CNRT
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
May 2, 2022 RCCK
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 18, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 18, 2022 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Apr 18, 2022 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Aug 31, 2021 GNS3
LETTER OF SUSPENSION E-MAILED
Aug 31, 2021 GNSL
SUSPENSION LETTER WRITTEN
Aug 31, 2021 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 4, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 4, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 4, 2021 TROA
REFUSAL PROCESSED BY IB
Mar 15, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Feb 22, 2021 RFCS
REFUSAL PROCESSED BY MPU
Feb 22, 2021 RFRR
APPLICATION FILING RECEIPT MAILED
Feb 16, 2021 MAFR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Feb 13, 2021 RFCR
NON-FINAL ACTION WRITTEN
Feb 12, 2021 CNRT
ASSIGNED TO EXAMINER
Feb 12, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 12, 2021 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Feb 11, 2021 REPR